Table 2 General and clinical data of patients in the training and validation sets
| Â | Training set | Verification set | Statistical value | P value |
|---|---|---|---|---|
N = 151 | N = 65 |  |  | |
Age | 55.0 [47.0;64.0] | 56.0 [46.0;64.0] | Z= -0.174 | 0.868 |
Gender | X2 < 0.001 | 1.000 | ||
 Male | 130 (86.1%) | 56 (86.2%) |  |  |
 Female | 21 (13.9%) | 9 (13.8%) |  |  |
BMI (kg/m2, x ± s) | 25.7 [23.9;27.8] | 25.0 [23.4;27.5] | Z= -1.238 | 0.190 |
Heart Rate | 79.7 ± 12.5 | 80.0 ± 11.6 | t = 0.207 | 0.837 |
Systolic blood pressure (mmHg) | 124 [112;137] | 123 [113;136] | Z= -1.342 | 0.996 |
Diastolic blood pressure (mmHg, x ± s) | 80.1 ± 13.8 | 80.4 ± 13.5 | t = 0.162 | 0.872 |
Medical history | ||||
Hypertension (Classification) | X2 = 2.141 | 0.544 | ||
 0 | 78 (51.7%) | 39 (60.0%) |  |  |
 1 | 11 (7.28%) |  2 (3.08%) |  |  |
 2 | 17 (11.3%) | 7 (10.8%) |  |  |
 3 | 45 (29.8%) | 17 (26.2%) |  |  |
Smoking history | X2 = 0.004 | 1.000 | ||
 No | 69 (45.7%) | 30 (46.2%) |  |  |
 Yes | 82 (54.3%) | 35 (53.8%) |  |  |
Dyslipidemia | X2 = 0.468 | 0.494 | ||
 No | 83 (55.0%) | 39 (60.0%) |  |  |
 Yes | 68 (45.0%) | 26 (40.0%) |  |  |
Diabetes | X2 = 0.221 | 0.638 | ||
 No | 114 (75.5%) | 51 (78.5%) |  |  |
 Yes | 37 (24.5%) | 14 (21.5%) |  |  |
History of drug use | ||||
Clopidogrel | X2 = 0.783 | 0.376 | ||
 No | 124 (82.1%) | 50 (76.9%) |  |  |
 Yes | 27 (17.9%) | 15 (23.1%) |  |  |
Beta-blocker | X2 = 0.056 | 0.814 | ||
 No | 81 (53.6%) | 36 (55.4%) |  |  |
 Yes | 70 (46.4%) | 29 (44.6%) |  |  |
ACEI/ARB | X2 = 0.354 | 0.552 | ||
 No | 84 (55.6%) | 39 (60.0%) |  |  |
 Yes | 67 (44.4%) | 26 (40.0%) |  |  |
Clinical data | ||||
Killip classification | X2 < 0.001 | 1.000 | ||
 I | 140 (92.7%) | 60 (92.3%) |  |  |
 II/III/IV | 11 (7.28%) | 5 (7.69%) |  |  |
ECG | X2 = 1.917 | 0.166 | ||
 STEMI | 124 (82.1%) | 48 (73.8%) |  |  |
 NSTEMI | 27 (17.9%) | 17 (26.2%) |  |  |
Criminal vessel | X2 = 5.225 | 0.073 | ||
 LAD | 86 (57.0%) | 27 (41.5%) |  |  |
 LCX | 20 (13.2%) | 15 (23.1%) |  |  |
 RCA | 45 (29.8%) | 23 (35.4%) |  |  |
Time from symptom onset to reperfusion (min) | 300 [180;540] | 300 [210;720] | Z= -2.350 | 0.208 |
GLU (mmol/L)* | 5.89 [5.10;7.32] | 5.71 [4.94;7.09] | Z= -1.422 | 0.246 |
HbA1c (%) | 6.00 [5.70;6.90] | 5.80 [5.60;6.50] | Z= -0.387 | 0.115 |
CRP (mg/L) | 27.5 [11.7;60.6] | 27.6 [10.6;60.5] | Z= -3.945 | 0.974 |
PLT / LYM | 88.3 [70.2;106] | 88.1 [75.2;108] | Z= -0.016 | 0.562 |
AST (U/L) | 191 [99.5;330] | 191 [100;408] | Z= -8.294 | 0.917 |
ALT (U/L) | 45.0 [33.0;61.5] | 51.0 [35.0;68.0] | Z= -5.335 | 0.488 |
LDH (×102U/L) | 7.84 [4.99;12.0] | 8.93 [4.60;14.1] | Z= -7.538 | 0.428 |
CK (×103U/L) | 1.53 [0.78;3.93] | 1.60 [0.97;3.70] | Z= -8.247 | 0.812 |
CKMB (ng/ml) | 124 [53.8;272] | 189 [64.3;264] | Z= -7.336 | 0.646 |
HS-TnT (×103ng/L) | 3.59 [1.68;6.88] | 3.75 [1.75;7.29] | Z= -9.372 | 0.981 |
NT-proBNP (×103pg/L) | 1.12 [0.65;1.89] | 1.01 [0.45;1.91] | Z= -3.048 | 0.294 |
SS (×10) * | 2.25 [1.50;2.85] | 2.15 [1.60;2.80] | Z= -7.568 | 0.759 |